Efeitos hemodinamicos agudos da bupropiona e da nicotina em cães anestesiados

AUTOR(ES)
DATA DE PUBLICAÇÃO

2006

RESUMO

The act of smoking is a habit with serious consequences for the public health. According to the World Organization of Health to smoke cigarette is the main cause of cardiovascular death and breathing diseases. Epidemical data show that for the next 20 years, cardiovascular diseases will be the main cause of death in the world. Besides, chronic obstructive pulmonary disease is the forth main death cause in United States of America. Smoking is considered the main risk factor for the development of these diseases. On the other hand the interruption or cessation of smoking reduces the risk of cardiovascular diseases. Bupropion, initially used as an antidepressant, has also been used as an anti-smoking agent, with a success rate of <30%. Studies on the simultaneous use of nicotine and bupropion have reported cessation of smoking within a six month period. Although there is considerable information on the effectiveness and safety of bupropion plus nicotine, little is known about the acute cardiovascular effects of this pharmacological association. In this study, we investigated the acute hemodynamic effects of bupropion alone and in association with nicotine in anesthetized dogs. In the two first studies bupropion hemodynamic parameters with simple doses from 3 to 6 mg/kg and in accumulative doses were investigated. Bupropion administered either in bolus injections (3 or 6 mg/kg, i.v.) or in cumulative doses of 0.01, 0.1, 1, 3 and 10 mg/kg showed, in both studies, a significant increase of mean pulmonary arterial pressure and pulmonary vascular resistance index. These results show that bupropion can elevate the pulmonary pressure. In the third phase of the study, using the same methodology, it was evaluated bupropion hemodynamic parameters (3 mg/kg), administered in injections, "in bolus ", isolated and in association with nicotine (75 µg/kg). Bupropion, either alone or together with nicotine, had no significant effect on the cardiac index (CI; 4.7±0.2 versus 4.3±0.1 and 3.5±0.3 versus 3.4±0.3 L.min-1.m2, respectively; mean+SEM) and mean arterial pressure (MAP; 134±5.0 versus 145±11.0 and 118±5.0 versus 133±10.5 mmHg, respectively). However, there was a significant increase in the mean pulmonary artery pressure (MPAP; 20±0.8 versus 25±1.6 and 18±1.3 versus 25±1.6 mmHg, respectively; P<0.05) and pulmonary vascular resistance index (PVRI; 194±11 versus 272±21 and 206±32 versus 307±42 dyn.cm-5m-2, respectively; P<0.05). In conclusion, these results show that bupropion alone or in association with nicotine does not markedly affect most hemodynamic parameters of the systemic circulation, although the significant increase in MPAP and PVRI can elevate the pulmonary pressure

ASSUNTO(S)

hipertensão pulmonar pressão arterial abandono do habito de fumar nicotina tabaco

ACESSO AO ARTIGO

Documentos Relacionados